Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors
- PMID: 30366604
- DOI: 10.1016/j.surg.2018.09.006
Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors
Abstract
Background: Patients with gastroenteropancreatic neuroendocrine tumors often present with stage IV disease. Primary tumor resection in these patients remains controversial. Herein, we studied the impact of primary tumor removal, identified variables associated with prolonged survival for each neuroendocrine tumor subtype, and determined factors that influence surgeons to perform primary tumor resection.
Methods: Patients with metastatic gastroenteropancreatic neuroendocrine tumors diagnosed from 2004 to 2014 were identified from the National Cancer Database. Nested Cox proportional hazards and logistic regression models were used to assess variables associated with survival and primary resection.
Results: A total of 14,510 patients met inclusion criteria. On multivariable analysis, resection of the primary tumor and grade 1 or 2 tumors was associated with prolonged survival in all subtypes (P < .001). Organ-specific variables associated with prolonged survival in patients undergoing primary tumor resection included the following: low grade for all organs; young age for pancreatic, small intestinal, colonic, and rectal neuroendocrine tumor; tumor size for colonic and rectal neuroendocrine tumor; and tumor location for colonic neuroendocrine tumor. Low tumor grade was found to be significantly associated with removal of the primary tumor across all organs.
Conclusion: This study is the first suggesting that primary tumor resection is associated with prolonged survival for all gastro-entero-pancreatic NETs. Additional variables related to survival for each NET subtype were identified and might help select patients who benefit from primary tumor removal.
Keywords: Neuroendocrine tumors; carcinoid tumors; colorectal neoplasms; gastrointestinal neoplasms; pancreatic neoplasms.
Copyright © 2018 Elsevier Inc. All rights reserved.
Similar articles
-
Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection.Surgery. 2019 Mar;165(3):657-663. doi: 10.1016/j.surg.2018.09.008. Epub 2018 Oct 28. Surgery. 2019. PMID: 30377003 Free PMC article.
-
Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis.Cancer Med. 2019 Sep;8(11):5128-5136. doi: 10.1002/cam4.2431. Epub 2019 Jul 22. Cancer Med. 2019. PMID: 31328428 Free PMC article.
-
Palliative resection of primary site in advanced gastroenteropancreatic neuroendocrine tumors improves survivals.Turk J Gastroenterol. 2019 Oct;30(10):910-916. doi: 10.5152/tjg.2019.19168. Turk J Gastroenterol. 2019. PMID: 31625933 Free PMC article.
-
GEP-NETS update: a review on surgery of gastro-entero-pancreatic neuroendocrine tumors.Eur J Endocrinol. 2014 Oct;171(4):R153-62. doi: 10.1530/EJE-14-0173. Epub 2014 Jun 11. Eur J Endocrinol. 2014. PMID: 24920289 Review.
-
Curative and palliative surgery in patients with neuroendocrine tumors of the gastro-entero-pancreatic (GEP) tract.Rev Endocr Metab Disord. 2018 Jun;19(2):169-178. doi: 10.1007/s11154-018-9469-9. Rev Endocr Metab Disord. 2018. PMID: 30280290 Review.
Cited by
-
Predictive value of the preoperative prognostic nutritional index for postoperative progression in patients with pancreatic neuroendocrine neoplasms.Front Nutr. 2022 Sep 8;9:945833. doi: 10.3389/fnut.2022.945833. eCollection 2022. Front Nutr. 2022. PMID: 36159473 Free PMC article.
-
Primary Tumor Resection and Its Implications in the Modern Treatment Era of Metastatic Small Bowel Neuroendocrine Tumors : Editorial on: "Morbidity and Outcomes of Primary Tumor Management in Patients with Widely Metastatic Well-Differentiated Small Bowel Neuroendocrine Tumors".Ann Surg Oncol. 2024 Apr;31(4):2187-2189. doi: 10.1245/s10434-023-14836-y. Epub 2024 Jan 2. Ann Surg Oncol. 2024. PMID: 38167812 No abstract available.
-
Early-onset pancreatic neuroendocrine neoplasms: A distinct disease with improved survival compared with old individuals.Front Endocrinol (Lausanne). 2023 Apr 4;14:1025485. doi: 10.3389/fendo.2023.1025485. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37082129 Free PMC article.
-
Risk factors, prognostic factors and nomograms for distant metastasis in colorectal neuroendocrine neoplasms: a SEER-based study.Transl Cancer Res. 2025 Mar 30;14(3):1576-1595. doi: 10.21037/tcr-24-2018. Epub 2025 Mar 4. Transl Cancer Res. 2025. PMID: 40224977 Free PMC article.
-
Long-term Outcomes of Surgical Treatment for Pancreatic Neuroendocrine Neoplasm With Synchronous Hepatic Metastasis: A Multicenter Retrospective Cohort Study.Pancreas. 2025 Mar 1;54(3):e179-e187. doi: 10.1097/MPA.0000000000002417. Epub 2024 Nov 18. Pancreas. 2025. PMID: 39999310 Free PMC article.
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous